Literature DB >> 27609529

Faecal and Serum Metabolomics in Paediatric Inflammatory Bowel Disease.

Kaija-Leena Kolho1, Alberto Pessia2, Tytti Jaakkola1, Willem M de Vos3,4,5, Vidya Velagapudi2.   

Abstract

BACKGROUND: Inflammatory bowel disease [IBD] is considered to result from the interplay between host and intestinal microbiota but its pathogenesis is incompletely understood. While IBD in adults has shown to be associated with marked changes in body fluid metabolomics, there are only few studies in children. Hence, this prospective study addressed the faecal and serum metabolomics in newly diagnosed paediatric IBD.
METHODS: Paediatric patients with IBD undergoing diagnostic endoscopies and controls also with endoscopy but no signs of inflammation provided blood and stool samples in a tertiary care hospital. Blood inflammatory markers and faecal calprotectin levels were determined. The serum and faecal metabolomics were determined using ultra-high pressure liquid chromatography coupled to a mass spectrometer.
RESULTS: Serum and faecal metabolite profiles in newly diagnosed paediatric IBD patients were different from healthy controls and categorized Crohn's disease and ulcerative colitis [UC] patients into separate groups. In serum, amino acid metabolism, folate biosynthesis and signalling pathways were perturbed in Crohn's disease; in UC also sphingolipid metabolic pathways were perturbed when compared to controls. In faecal samples, there was an increased level of several metabolites in UC in contrast to low or intermediate levels in Crohn's disease. There was a clear correlation with the level of inflammation, i.e. faecal calprotectin levels and the profile of various biologically important metabolites [carnosine, ribose and, most significantly, choline].
CONCLUSION: Characterization of inflammatory pattern using metabolomics analysis is a promising tool for better understanding disease pathogenesis of paediatric IBD.
Copyright © 2016 European Crohn’s and Colitis Organisation (ECCO). Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com

Entities:  

Keywords:  Children; Crohn’s disease; ulcerative colitis

Mesh:

Substances:

Year:  2017        PMID: 27609529     DOI: 10.1093/ecco-jcc/jjw158

Source DB:  PubMed          Journal:  J Crohns Colitis        ISSN: 1873-9946            Impact factor:   9.071


  53 in total

Review 1.  Gut microbiota-derived metabolites as key actors in inflammatory bowel disease.

Authors:  Aonghus Lavelle; Harry Sokol
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-02-19       Impact factor: 46.802

Review 2.  Colonization resistance: metabolic warfare as a strategy against pathogenic Enterobacteriaceae.

Authors:  Nicolas G Shealy; Woongjae Yoo; Mariana X Byndloss
Journal:  Curr Opin Microbiol       Date:  2021-10-20       Impact factor: 7.934

Review 3.  Multiomics to elucidate inflammatory bowel disease risk factors and pathways.

Authors:  Manasi Agrawal; Kristine H Allin; Francesca Petralia; Jean-Frederic Colombel; Tine Jess
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2022-03-17       Impact factor: 73.082

Review 4.  Dietary Patterns and Gut Microbiota: The Crucial Actors in Inflammatory Bowel Disease.

Authors:  Pandi He; Leilei Yu; Fengwei Tian; Hao Zhang; Wei Chen; Qixiao Zhai
Journal:  Adv Nutr       Date:  2022-10-02       Impact factor: 11.567

Review 5.  Microbiome risk profiles as biomarkers for inflammatory and metabolic disorders.

Authors:  Amira Metwaly; Sandra Reitmeier; Dirk Haller
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2022-02-21       Impact factor: 73.082

Review 6.  Recent Advances in the Etiopathogenesis of Inflammatory Bowel Disease: The Role of Omics.

Authors:  Eleni Stylianou
Journal:  Mol Diagn Ther       Date:  2018-02       Impact factor: 4.074

Review 7.  Microbial genes and pathways in inflammatory bowel disease.

Authors:  Melanie Schirmer; Ashley Garner; Hera Vlamakis; Ramnik J Xavier
Journal:  Nat Rev Microbiol       Date:  2019-08       Impact factor: 60.633

8.  Alterations in Lipid, Amino Acid, and Energy Metabolism Distinguish Crohn's Disease from Ulcerative Colitis and Control Subjects by Serum Metabolomic Profiling.

Authors:  Elizabeth A Scoville; Margaret M Allaman; Caroline T Brown; Amy K Motley; Sara N Horst; Christopher S Williams; Tatsuki Koyama; Zhiguo Zhao; Dawn W Adams; Dawn B Beaulieu; David A Schwartz; Keith T Wilson; Lori A Coburn
Journal:  Metabolomics       Date:  2017-12-29       Impact factor: 4.290

9.  Metabolic modelling reveals broad changes in gut microbial metabolism in inflammatory bowel disease patients with dysbiosis.

Authors:  Almut Heinken; Johannes Hertel; Ines Thiele
Journal:  NPJ Syst Biol Appl       Date:  2021-05-06

10.  Multi-omic Analysis of the Interaction between Clostridioides difficile Infection and Pediatric Inflammatory Bowel Disease.

Authors:  Frederic D Bushman; Maire Conrad; Yue Ren; Chunyu Zhao; Christopher Gu; Christopher Petucci; Min-Soo Kim; Arwa Abbas; Kevin J Downes; Nina Devas; Lisa M Mattei; Jessica Breton; Judith Kelsen; Sarah Marakos; Alissa Galgano; Kelly Kachelries; Jessi Erlichman; Jessica L Hart; Michael Moraskie; Dorothy Kim; Huanjia Zhang; Casey E Hofstaedter; Gary D Wu; James D Lewis; Joseph P Zackular; Hongzhe Li; Kyle Bittinger; Robert Baldassano
Journal:  Cell Host Microbe       Date:  2020-08-20       Impact factor: 31.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.